Vidadi Yusibov

Human-derived, plant-produced monoclonal antibody for the treatment of anthrax.

Peptide-based candidate vaccine against respiratory syncytial virus.

Inducible expression in plants by virus-mediated transgene activation.

The potential of plant virus vectors for vaccine production.

Engineering and expression of the intracellular domain of insulinoma-associated tyrosine phosphatase (IA-2ic), a type 1 diabetes autoantigen, in plants.

Anti-cancer activity of plant-produced HPV16 E7 vaccine.

Immunogenicity of a subunit vaccine against Bacillus anthracis.

A plant-produced plague vaccine candidate confers protection to monkeys.

Plants as alternative systems for production of vaccines.

Production of recombinant proteins in clonal root cultures using episomal expression vectors.

Plant-expressed HA as a seasonal influenza vaccine candidate.

Development of a new cucumber mosaic virus-based plant expression vector with truncated 3a movement protein.

Recent progress in the development of plant derived vaccines.

Plants as biofactories.

Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza.

Transient protein expression in three Pisum sativum (green pea) varieties.

Immunogenicity of hemagglutinin from A/Bar-headed Goose/Qinghai/1A/05 and A/Anhui/1/05 strains of H5N1 influenza viruses produced in Nicotiana benthamiana plants.

A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague.

An E7-based therapeutic vaccine protects mice against HPV16 associated cancer.

Plant-produced human growth hormone shows biological activity in a rat model.

Using plant cells as influenza vaccine substrates.

A launch vector for the production of vaccine antigens in plants.

A plant-produced influenza subunit vaccine protects ferrets against virus challenge.

A novel two-component Tobacco mosaic virus-based vector system for high-level expression of multiple therapeutic proteins including a human monoclonal antibody in plants.

Plant-produced microbial vaccines: Alexander V. Karasev, editor: Current topics in microbiology and immunology 2009; v. 332.

Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza.

Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity.

A non-glycosylated, plant-produced human monoclonal antibody against anthrax protective antigen protects mice and non-human primates from B. anthracis spore challenge.

Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond.

Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice.

A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum.

Co-expression of multiple target proteins in plants from a tobacco mosaic virus vector using a combination of homologous and heterologous subgenomic promoters.

An influenza N1 neuraminidase-specific monoclonal antibody with broad neuraminidase inhibition activity against H5N1 HPAI viruses.

A plant-based system for rapid production of influenza vaccine antigens.

A cryohistological protocol for preparation of large plant tissue sections for screening intracellular fluorescent protein expression.

Formulation development of a plant-derived H1N1 influenza vaccine containing purified recombinant hemagglutinin antigen.

Production of non-glycosylated recombinant proteins in Nicotiana benthamiana plants by co-expressing bacterial PNGase F.

Comparative characterization of the glycosylation profiles of an influenza hemagglutinin produced in plant and insect hosts.

The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants.

Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.

Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults.

A plant-produced H1N1 trimeric hemagglutinin protects mice from a lethal influenza virus challenge.

A plant-produced protective antigen vaccine confers protection in rabbits against a lethal aerosolized challenge with Bacillus anthracis Ames spores.

In vivo deglycosylation of recombinant proteins in plants by co-expression with bacterial PNGase F.

Hybrid viral vectors for vaccine and antibody production in plants.

Plant-produced human recombinant erythropoietic growth factors support erythroid differentiation in vitro.

Hairy roots as a vaccine production and delivery system.

Green algae Chlamydomonas reinhardtii possess endogenous sialylated N-glycans.

Deletions within the 3' non-translated region of Alfalfa mosaic virus RNA4 do not affect replication but significantly reduce long-distance movement of chimeric Tobacco mosaic virus.

Functional testing of an inhalable nanoparticle based influenza vaccine using a human precision cut lung slice technique.

Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults.

A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice.

A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.